Literature DB >> 2540934

Screening with a shell vial assay for antiviral activity against cytomegalovirus.

A Telenti1, T F Smith.   

Abstract

An assay based on the shell vial cell culture (SVA) was devised to assess differences in fluorescence patterns of 8 cytomegalovirus (CMV) strains incubated in the presence or absence of three antiviral substances. The drug concentrations selected for in vitro testing were in the range of peak serum levels achievable in humans (ganciclovir 20 microM, acyclovir 80 microM, and phosphonoformic acid 300 microM). Four days after inoculation of the shell vials, the cell monolayer was fixed, stained with a mixture of monoclonal antibodies to early and late antigens of CMV, and reacted with antimouse fluorescein-labeled globulin. Twenty microM of ganciclovir in the media inhibited the formation of plaque-like foci and specific cytoplasmic fluorescence of laboratory strain AD169 and four clinical isolates. Two documented resistant strains exhibited partial inhibition at 20 microM, and a clinical isolate exhibited incomplete inhibition in three or four occasions. None of the strains was fully inhibited by 80 microM of acyclovir; however, different degrees of partial inhibition were observed. All isolates exhibited high-grade inhibition by 300 microM of phosphonoformic acid. The SVA can be used as a simple screening test for anti-CMV substances and as a screening of CMV resistance to ganciclovir prior to quantitative testing by the more complex plaque reduction assay.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540934     DOI: 10.1016/0732-8893(89)90036-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors:  Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  A rapid method for screening large numbers of environmental microorganisms for antiviral activity.

Authors:  C Maullu; G Lampis; D Deidda; S Petruzzelli; R Pompei
Journal:  Appl Environ Microbiol       Date:  1998-03       Impact factor: 4.792

Review 5.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 6.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

7.  Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

Authors:  M A Slavin; R R Bindra; C A Gleaves; M B Pettinger; R A Bowden
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.